To evaluate the potential of C9orf50 as a cancer therapeutic target, we investigated the antitumor effects of C9orf50 inhibition via direct intratumoral administration of C9orf50 siRNA (siC9ORF50) in MC38 tumor‐bearing mice (Figure 8A). Here, C9orf50 is linked to cancer.